Company intelligence / Profile preview

Prestige Biopharma Limited

Ownership: Private
Employees: ~54
Development stage: Commercial

Overview

Prestige Biopharma reported its first-ever net profit of 32.1 billion won ($22 million) for the second half of 2024, primarily fueled by milestone payments from Tuznue (trastuzumab), its Herceptin biosimilar which received European approval in 2024[7]. The company has a diverse portfolio of biosimilars and novel antibody drugs in various stages of development.

Therapeutic areas: OncologyImmunologyEndocrinologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodies (bsAbs)Fusion protein antibodies (fusion-Abs)BiosimilarsVaccines
Industry: Biotech

Drug pipeline

30 assets

ulenistamab

29 more assets in the full pipeline.

Request access →

Partnerships

Dr. Reddy's

Beyond the preview

Go deeper on Prestige Biopharma Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prestige Biopharma Limited.

Explore the full profile